Meta-Analysis: Tirzepatide Produces About 4.8 kg More Weight Loss Than Semaglutide
Pooling data from 12 studies, tirzepatide produced nearly 5 kg more weight loss and was 2–3 times more likely to help patients reach major weight loss milestones compared to semaglutide.
Quick Facts
What This Study Found
Across 12 studies, tirzepatide produced significantly greater weight loss than semaglutide. Tirzepatide users lost an additional 4.61% body weight (95% CI: -6.03 to -3.20, p<0.00001) and 4.76 kg more (95% CI: -6.09 to -3.42, p<0.00001) than semaglutide users.
Tirzepatide users were also significantly more likely to reach key weight loss milestones: 1.52× more likely to lose ≥5%, 2.33× more likely to lose ≥10%, 2.82× more likely to lose ≥15%, and 2.28× more likely to lose ≥20% of body weight. All comparisons were statistically significant.
Key Numbers
12 studies · MD -4.61% body weight · MD -4.76 kg · OR 2.82 for ≥15% loss · OR 2.28 for ≥20% loss · p<0.00001 for most comparisons
How They Did This
Systematic review and meta-analysis searching Europe PMC, Medline, Scopus, and Cochrane Library for RCTs and observational studies directly comparing tirzepatide and semaglutide for weight loss. Pooled analyses used random-effects models to calculate mean differences and odds ratios with 95% confidence intervals. Heterogeneity was assessed using I² statistics.
Why This Research Matters
This is the first meta-analysis to directly compare the two most prominent weight loss peptide drugs head-to-head. The consistent advantage of tirzepatide across all weight loss thresholds provides the strongest pooled evidence to date for choosing between these therapies.
The Bigger Picture
The tirzepatide vs. semaglutide comparison is the central question in obesity pharmacotherapy today. This meta-analysis provides the most comprehensive pooled evidence to date favoring tirzepatide's dual GIP/GLP-1 mechanism for weight reduction. However, treatment choice also depends on safety, tolerability, cost, and availability — factors this analysis did not address.
What This Study Doesn't Tell Us
High heterogeneity (I²=87–97%) across all outcomes suggests substantial variability between studies in populations, doses, and follow-up periods. The inclusion of observational studies alongside RCTs limits causal inference. The analysis did not assess safety profiles, cost-effectiveness, or long-term outcomes beyond the study periods.
Questions This Raises
- ?Does tirzepatide's weight loss advantage translate to better cardiovascular and metabolic outcomes long-term?
- ?How do side effect profiles compare at equivalent weight-loss-producing doses?
- ?Will cost and insurance coverage differences offset the clinical advantage of tirzepatide?
Trust & Context
- Key Stat:
- 4.76 kg more Additional weight loss with tirzepatide over semaglutide across 12 pooled studies
- Evidence Grade:
- As a systematic review and meta-analysis pooling 12 studies, this represents a high level of evidence synthesis. However, high heterogeneity (I²>87% across outcomes) and inclusion of observational studies temper the certainty somewhat.
- Study Age:
- Published in 2026, this is the most current meta-analysis comparing these two leading weight loss peptide drugs, incorporating the latest available trial and real-world data.
- Original Title:
- Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.
- Published In:
- Obesity research & clinical practice (2026)
- Authors:
- Zufry, Hendra, Hariyanto, Timotius Ivan
- Database ID:
- RPEP-16627
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
How much more weight do people lose on tirzepatide vs. semaglutide?
According to this meta-analysis of 12 studies, people on tirzepatide lost about 4.76 kg (10.5 lbs) more than those on semaglutide on average. They were also about 2.8 times more likely to achieve 15% or greater body weight loss.
Does this mean tirzepatide is definitively better than semaglutide?
For weight loss specifically, the pooled evidence favors tirzepatide. However, this analysis did not compare safety profiles, side effects, long-term outcomes, or cost-effectiveness. The best choice depends on individual health factors, insurance coverage, and tolerability — both drugs produce clinically meaningful weight loss.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-16627APA
Zufry, Hendra; Hariyanto, Timotius Ivan. (2026). Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.. Obesity research & clinical practice. https://doi.org/10.1016/j.orcp.2026.02.002
MLA
Zufry, Hendra, et al. "Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.." Obesity research & clinical practice, 2026. https://doi.org/10.1016/j.orcp.2026.02.002
RethinkPeptides
RethinkPeptides Research Database. "Head-to-head comparison of tirzepatide and semaglutide for w..." RPEP-16627. Retrieved from https://rethinkpeptides.com/research/zufry-2026-headtohead-comparison-of-tirzepatide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.